The U.S. Market Isn’t What You Think - A Workshop on How Healthtech Companies Actually Generate Revenue

The article frames U.S. expansion as a key milestone for Nordic healthtech firms, but highlights that many fail because they misread how value converts into revenue in the U.S. market. It previews an upcoming Health3-2-1 workshop led by Elizabeth Jennings of Venture Atlas Labs focused on this commercialization gap. The piece is largely educational and strategic rather than event-driven, with limited immediate market impact.

Analysis

The key market implication is not that U.S. expansion is hard; it is that the revenue step-up is governed by buyer behavior, not product quality. For Nordic healthtech vendors, the real bottleneck is usually conversion from clinical interest to procurement approval, reimbursement eligibility, and budget-owner signoff — a multi-layer sales motion that stretches cash burn by quarters and compresses implied CAC payback versus what management teams model in Europe.

That creates a second-order winner set: U.S.-native channel partners, RCM platforms, distributors, and implementation-heavy incumbents that already sit inside reimbursement and enterprise purchasing workflows. The losers are capitalized early-stage international entrants that assume product-led growth will carry them; they often need materially more U.S. headcount, local KOL investment, and compliance spend than forecast, which can force down-rounds or strategic sales within 6-18 months if conversion metrics stall.

The contrarian read is that the problem is less “Europe versus U.S.” and more “value articulation versus monetization architecture.” Companies that can package evidence into budget-holder language — reduced readmissions, fewer denials, shorter LOS, or lower admin labor — can still win, but they need an enterprise distribution strategy from day one. The market is likely underestimating how much of the U.S. opportunity accrues to firms that sell the billing, workflow, and implementation layers around care delivery rather than the core clinical algorithm itself.

Catalyst-wise, watch for pilot-to-contract conversion over the next 2-3 quarters, not headline partnership announcements. If management teams start adding U.S. sales reps without corresponding signed enterprise references or reimbursement pathways, that is usually an early warning that growth is being bought, not earned.

Key Decisions for Investors

• Avoid underwriting Nordic healthtech venture rounds on TAM expansion alone; require evidence of U.S. pilot-to-paid conversion within 2-3 quarters and reimbursement/budget-owner mapping before participating.
• In private markets, prefer second-order winners: U.S.-based RCM, implementation, and workflow software providers that benefit from foreign entrants needing local integration; structure as long exposure where possible.
• For public comparables, favor profitable U.S. healthcare SaaS/IT names with distribution leverage over clinical-point-solution vendors that depend on direct enterprise sales expansion; use a 6-12 month horizon.
• Short or avoid companies that announce U.S. entry plus hiring spikes but lack signed multi-site deployments; the risk/reward skews negative if CAC expands faster than bookings over the next 2-4 quarters.
• If accessible, pair long U.S. incumbents with strong reimbursement/sales infrastructure against short international healthtech newcomers in the same workflow segment to isolate execution and monetization risk.